Effect of insulin therapy on nonglycemic variables during acute illness

Endocrine Practice

Volumn 10, Issue SUPPL. 2, 2004, Pages 63-70

  Hirsch, Irl B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CYTOKINE; FATTY ACID; GLUCOSE; GROWTH PROMOTOR; INSULIN; NITRIC OXIDE; POTASSIUM;

ACUTE DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; METABOLISM; REVIEW;

ACUTE DISEASE; CYTOKINES; DRUG COMBINATIONS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GROWTH SUBSTANCES; HUMANS; INFLAMMATION MEDIATORS; INSULIN; NITRIC OXIDE; POTASSIUM;

EID: 4644343842     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.10.s2.63     Document Type: Conference Paper

References (59)

1. Bliss M. The Discovery of Insulin. London: Faber and Faber, 1982.
2. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
3. Malmberg K (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction [DIGAMI] Study Group). Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512-1515.
4. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125:1007-1021.
5. Guazzi M, Tumminello G, Matturri M, Guazzi MD. Insulin ameliorates exercise ventilatory efficiency and oxygen uptake in patients with heart failure-type 2 diabetes comorbidity. J Am Coll Cardiol. 2003;42:1044-1050.
6. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982.
7. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152-1156.
8. van der Horst IC, Zijlstra F, van't Hof AW, et al (Zwolle Infarct Study Group). Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin- potassium study; a randomized trial. J Am Coll Cardiol. 2003;42:784-791.
9. Van den Berghe G, de Zegher F, Bouillon R. Clinical review 95: acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab. 1998;83:1827-1834.
10. Chrousos GP. The hypothalamic-pituitary axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351-1362.
11. van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab. 1990;71:1567-1572.
12. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
13. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
14. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
15. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149-2153.
16. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:4219-4225.
17. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation [erratum in N Engl J Med. 1999;340:1376.]. N Engl J Med. 1999;340:448-454.
18. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem. 1999;265:501-523.
19. Zeidler C, Kanz L, Hurkuck F, et al. In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood. 1992;80:2740-2745.
20. Moldawer LL, Copeland EM III. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer. 1997;79:1828-1839.
21. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24:163-172.
22. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
23. Yamashita N, Hoshida S, Otsu K, Asahi M, Kuzuya T, Hori M. Exercise provides direct biphasic cardioprotection via manganese superoxide dismutase activation. J Exp Med. 1999;189:1699-1706.
24. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
25. Cain BS, Harken AH, Meldrum DR. Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion. J Mol Cell Cardiol. 1999;31:931-947.
26. Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res. 1999;85:185-199.
27. Ferrari R. Tumor necrosis factor in CHF: a double facet cytokine. Cardiovasc Res. 1998;37:554-559.
28. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364-2367.
29. Dandona P, Aljada A, Bandyopadhyay A. The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care. 2003;26:516-519.
30. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear factor kappaβ and stimulates Ikappaβ in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001;86: 3257-3265.
31. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NFkappaβ and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001;86:450-453.
32. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts anti-inflammatory effects in critically ill patients and counteracts the adverse effects of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88:1082-1088.
33. Dandona P, Thusu K, Hafeez R, Abdel-Rahman E, Chaudhuri A. Effect of hydrocortisone on oxygen free radical generation by mononuclear cells. Metabolism. 1998;47:788-791.
34. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci. 1993;14:436-441.
35. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaβ induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res. 2000;87:746-752.
36. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-2072.
37. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
38. Yudkin JS, Panahloo A, Stehouwer C, et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in type II diabetic subjects. Diabetologia. 2000;43:1099-1106.
39. McCaffrey TA, Fu C, Du B, et al. High-level expression of Erg-1 and Erg-1-expressible genes in mouse and human atherosclerosis. J Clin Invest. 2000;105:653-662.
40. Aljada A, Ghanim H, Mohanty P, Kapur H, Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Erg)-1 expression in mononuclear cells (MNC) and reduced plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab. 2002;87:1419-1422.
41. Shapiro SD. Diverse roles of macrophage matrix metallo-proteinases in tissue destruction and tumor growth. Thromb Haemost. 1999;82:846-849.
42. Ghanim H, Mohanty P, Aljada A, Chowhan S, Tripathy D, Dandona P. Insulin reduces the pro-inflammatory transcription factor, activation protein-1 (AP-1), in mononuclear cells (MNC) and plasma matrix metalloproteinase-9 (MMP-9) concentration [abstract]. Diabetes. 2001;50(Suppl 1):A408.
43. Steinberg HO, Brechtel G, Johnson N, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric-oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:1172-1179.
44. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894-898.
45. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 2000;49:147-150.
46. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20:545-550.
47. Alonso D, Radomski MW. Nitric oxide, platelet function, myocardial infarction, and reperfusion therapies. Heart Fail Rev. 2003;8:47-54.
48. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:2511-2515.
49. Chaudhuri A, Kanjwal Y, Mohanty P, et al. Insulin-induced vasodilatation of internal carotid artery. Metabolism. 1999;48:1470-1473.
50. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785-789.
51. Boden G. Effects of free fatty acids on gluconeogenesis and glycogenolysis. Life Sci. 2003;72:977-988.
52. Kurien VA, Oliver MF. Serum-free-fatty-acids after acute myocardial infarction and cerebral vascular occlusion. Lancet. 1966;2:122-127.
53. Jouven X, Charles MA, Desnos M, Ducimetiere P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation. 2001;104:756-761.
54. Soloff LA. Arrhythmias following infusions of fatty acids. Am Heart J. 1970;80:671-674.
55. Manzella D, Grella R, Marfella R, Giugliano D, Paolisso G. Elevated post-prandial free fatty acids are associated with cardiac sympathetic overactivity in type II diabetic patients [letter]. Diabetologia. 2002;45:1737-1738.
56. Egan BM, Greene EL, Goodfriend TL. Nonesterified fatty acids in blood pressure control and cardiovascular complications. Curr Hypertens Rep. 2001;3:107-116.
57. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230-1239.
58. Nilsson L, Banfi C, Diczfalusy U, Tremoli E, Hamsten A, Eriksson P. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol. 1998;18:1679-1685.
59. Egan BM, Hennes MM, Stepniakowski KT, O'Shaughnessy IM, Kissebah AH, Goodfriend TL. Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension. 1996;27(3 Pt 2):723-728.